Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hoping To Smooth Relations With FDA, Sarepta Moves On From CEO Garabedian

This article was originally published in The Pink Sheet Daily

Executive Summary

Seeing Garabedian’s relationship with FDA as strained, Sarepta promotes Chief Medical Officer to interim CEO post in hopes of keeping eteplirsen on track for a mid-year NDA filing.


Related Content

Eteplirsen Approval Reflected FDA's Conflict On Accelerated Approval – Former Sarepta CEO


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts